Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-29

Study Completion Date

2029-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goals of this clinical trial are:

* demonstrate the safety of REGENERA breast implant in patients undergoing lumpectomy of malignant breast lesions
* demonstrate the safety and performance of REGENERA in terms of investigator's satisfaction, potential interference with current standard-of-care imaging techniques and occurrence of device-related serious adverse events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

REGENERA Implant in Excised Non-Malignant Breast Lesions

NCT04131972

Benign Breast Disease

COMPLETED NA

REGENERA Implant in Localized Non-malignant Breast Lesions Treated by Excision or Lumpectomy - Long-term Follow-up

NCT05533099

Breast Diseases

ACTIVE_NOT_RECRUITING

Implant-based Breast Reconstruction and Mastectomy With Fat Grafting After Breast Conserving Surgery and Radiotherapy

NCT06119633

Breast Cancer

COMPLETED NA

Reoperative Sentinel Lymph Node Biopsy in Patients With Recurrent Ipsilateral Breast Cancer

NCT06329089

Recurrent Breast Cancer

RECRUITING

Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy

NCT00616135

Breast Neoplasms Carcinoma, Ductal, Breast Mammaplasty +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:

* Screening
* Pre-surgery treatment
* Surgery and study device implant
* Post-surgery follow-up up to 5 years

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mastectomy, Segmental Breast Neoplasm Malignant Female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

REGENERA breast implant implantation

Single monolateral breast implant

Group Type EXPERIMENTAL

REGENERA breast implant implantation

Intervention Type DEVICE

Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:

* Screening
* Pre-surgery treatment
* Surgery and study device implant
* Post-surgery follow-up

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REGENERA breast implant implantation

Each patient will perform 13 study visits, and at each visit, all necessary study procedures will be performed according to the clinical investigation plan:

* Screening
* Pre-surgery treatment
* Surgery and study device implant
* Post-surgery follow-up

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female adult subject aged 40-70 years.
* Subject diagnosed with malignant breast lesion:
* monolateral nodular infiltrative carcinoma,
* without microcalcification,
* single or multifocal,
* included in an area with a maximum diameter of 4 cm,
* non-metastatic (M0).
* Subject with clinically negative axilla.
* Subject considered eligible for conservative breast surgery - BCS (Breast-Conserving Surgery, lumpectomy or quadrantectomy), leaving a volume deficit compatible with a REGENERA implant (available in two dried sizes) volume of 70 ml or 100 ml.
* Confirmation of malignant lesion (pT1, pT2, pN0, pN1) with no discordance between biopsy and radiological imaging.
* Adequate hematopoietic functions.
* Good general health and mentally sound.
* Subject able and willing to give written informed consent form.

Exclusion Criteria

* Subject with actual concomitant benign breast lesion (B2 and B3), unless present in the same mammary quadrant or in the contralateral breast.
* Subject with actual concomitant malignancies, lobular neoplasm, metastatic breast carcinoma, sarcoma, malignant phyllodes lesions, or Paget's disease.
* Axillary dissection planned as part of the breast lesion surgery.
* History of surgery, chemotherapy, neoadjuvant chemotherapy, or irradiation of the breast parenchyma object of the study.
* Skin retraction at the breast to be operated.
* Infection of the surgical site confirmed pre-operatively by clinical examination.
* Abnormal blood sugar and glycosylated hemoglobin.
* Hard smoker (more than 10 cigarettes a day).
* Acute or chronic severe renal insufficiency (creatinine values \>180 μmol/l).
* History of severe asthma or allergies (including allergy to anesthetics or contrast media).
* Autoimmune disease.
* Subjects who are known to be carriers of BCRA mutation.
* Inability to undergo MRI or allergy to contrast media.
* Systemic infections in an active phase.
* Immunocompromised patients (HIV).
* Pregnant or breastfeeding woman or woman who has nursed a child within 3 months prior to enrolment in the study.
* Subject who has participated in another interventional study within the past 3 months.
* Subject who received immunosuppressant therapy in the last 3 months.
* History of substance abuse (drug or alcohol).
* Non-collaborative patients (severe physical disabilities or psychiatric disorders, as per specialist opinion).

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No